Prostate cancer
Conditions
Interventions
Pescription dose is started from 36 Gy (RBE)/4fraction. 10 patients are treated in "
one-week"
groups. If DLT (acute grade 3 or more adverse events) is observed in less than 3 patients, dose-escalation is performed.
Pescription dose is started from 36 Gy (RBE)/4fraction. 10 patients are treated
two-weeks"
groups. If DLT (acute grade 3 or more adverse events) is observed in less than 3 patients, dose-escalation is performed.
Sponsors
Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) biopsy-proven prostate cancer 2) -T2cN0M0, PSA < 20 ng/ml, GS =<7 according to MRI, CT and bone scintigram 3) Performance Status (ECOG) of 0-1. 4) Expected prognosis > 6 months 5) Approved by document.
Exclusion criteria
Exclusion criteria: 1) Other therapies except for hormonal therapy 2) Previous radiation therapy to the pelvis 3) Ineligible dose constraints of risk organs 4) Castration resistant prostate cancer 5) Previous TUR-P 6) Active Double cancer 7) Presence of active double cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GI/GU adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical failure free survival, overall survival, disease free survival, dose volume analysis, and evaluation of QOL | — |
Countries
Japan
Contacts
Public ContactGoro Kasuya
QST Hospital , National Institutes for Quantum and Rad Treatment division
Outcome results
None listed